NCT00251420

Brief Summary

Therapeutic writing about one's emotions has been described previously (J Pennebaker: Emotions, disclosure and health. Am Psychol. Assoc 1995). The present project will compare the effects (if any) of writing about the emotional versus the physical consequences of lung disease on anxiety, perceived quality of life, and perceived health status.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2005

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 10, 2005

Completed
21 days until next milestone

Study Start

First participant enrolled

December 1, 2005

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
Last Updated

May 7, 2009

Status Verified

May 1, 2009

First QC Date

November 9, 2005

Last Update Submit

May 6, 2009

Conditions

COPDAsthma

Keywords

copdasthmaQoLPerceived health statusTrait anxiety

Outcome Measures

Primary Outcomes (3)

  • Quality of life

    prospective

  • Perceived health status

    prospective

  • Trait anxiety

    prospective

Secondary Outcomes (2)

  • Forced expiratory volume in 1 second (FEV1)

    prospective

  • 6-minute walking distance

    prospective

Interventions

writing about diseasePROCEDURE

writing about physical or emotional consequences of pulmonary disease

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of COPD (age between 35 and 70)
  • Clinical diagnosis of asthma (age between 20 and 60)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Glittreklinikken

Hakadal, Akershus, 1485, Norway

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveAsthma

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBronchial DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Einar Haave, Cand Psychol

    LHL Helse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 9, 2005

First Posted

November 10, 2005

Study Start

December 1, 2005

Study Completion

December 1, 2007

Last Updated

May 7, 2009

Record last verified: 2009-05

Locations

NO(1)